Targeted therapy plays a critical role in managing CRPC by attacking specific cancer cell mechanisms. For instance, PARP inhibitors like olaparib are used for patients with specific genetic mutations, such as BRCA1/2. Researchers continue to explore new targets to improve treatment outcomes.
